B. A. Ponder

发表

Genotype‐phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium

B. Ponder, S. Thibodeau, L. Mulligan, 1995, Journal of internal medicine.

Mutagenesis of mouse intestine in vivo using the Dlb-1 specific locus test: studies with 1,2-dimethylhydrazine, dimethylnitrosamine, and the dietary mutagen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline.

B. Ponder, A. Boobis, D. Winton, 1990, Cancer research.

CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2

John P. Bilezikian, Rajesh V. Thakker, Bruce A.J. Ponder, 2001 .

Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma.

B. Ponder, C. Healey, L. Mulligan, 1996, Cancer research.

Characterisation of germline mutations in the neurofibromatosis type 1 (NF1) gene.

S. Huson, P. Harper, M. Upadhyaya, 1995, Journal of medical genetics.

Paternal origin of new mutations in Von Recklinghausen neurofibromatosis

C. Mathew, B. Ponder, S. Huson, 1990, Nature.

The MEN II syndromes and the role of the ret proto-oncogene.

B. Ponder, Darrin P. Smith, D. Smith, 1996, Advances in cancer research.

Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.

B. Ponder, L. Mulligan, C. Eng, 1996, Cancer research.

Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors.

B. Ponder, B. Rollins, G. Shapiro, 1997, The Journal of clinical endocrinology and metabolism.

Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma.

B. Ponder, D. Wheeler, C. Eng, 1995, Journal of medical genetics.

Multiple endocrine neoplasia type 2.

B. A. Ponder, Lois M. Mulligan, 1994, European journal of cancer.